Recent Finacing
Recent Raise
EpimAb Biotherapeutics develops bispecific antibody therapeutics using its FIT‑Ig platform, advancing oncology-focused clinical and preclinical programs (EMB-01/02/06), operating R&D and manufacturing facilities in Shanghai and Suzhou.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
